{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:19:01Z","timestamp":1781662741114,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002784","name":"Canada Excellence Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["GC-202209-2024050"],"award-info":[{"award-number":["GC-202209-2024050"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013500","name":"Canadian Cardiovascular Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000860","name":"European Society of Cardiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020895","name":"Temerty Faculty of Medicine, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010785","name":"Canada First Research Excellence Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["CRC-2020-00353"],"award-info":[{"award-number":["CRC-2020-00353"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009408","name":"Brain Canada Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021784","name":"Ontario Ministry of Colleges and Universities","doi-asserted-by":"publisher","award":["ER21-16-146"],"award-info":[{"award-number":["ER21-16-146"]}],"id":[{"id":"10.13039\/501100021784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["202111FBD-47623-75801"],"award-info":[{"award-number":["202111FBD-47623-75801"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cardfail.2025.05.022","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T13:47:37Z","timestamp":1753969657000},"page":"732-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sodium-glucose Cotransporter-2 Inhibitor Initiation and Incident Dementia in Heart Failure With Diabetes: A Population-based Cohort Study"],"prefix":"10.1016","volume":"32","author":[{"given":"CHE-YUAN","family":"WU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ABHINAV","family":"SHARMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JODI D.","family":"EDWARDS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PETER P.","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. FANGYUN","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHO","family":"PODOLSKY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MOIRA K.","family":"KAPRAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KRISTA L.","family":"LANCT\u00d4T","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRADLEY J.","family":"MACINTOSH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUGO","family":"COGO-MOREIRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BAIJU R.","family":"SHAH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0030-8908","authenticated-orcid":false,"given":"WALTER","family":"SWARDFAGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cardfail.2025.05.022_bib0001","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCULATIONAHA.119.041022","article-title":"Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions","volume":"141","author":"Sharma","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.022_bib0002","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.022_bib0003","first-page":"1153","article-title":"2022 Canadian Cardiovascular Society Guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults","volume":"38","author":"Mancini","year":"2022","journal-title":"Can J Cardiol"},{"issue":"10354","key":"10.1016\/j.cardfail.2025.05.022_bib0004","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"10248","key":"10.1016\/j.cardfail.2025.05.022_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet (London, England)."},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.022_bib0006","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1038\/s41591-024-03049-9","article-title":"Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk","volume":"30","author":"Mobley","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.cardfail.2025.05.022_bib0007","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cardfail.2024.01.003","article-title":"Cognitive impairment in heart failure: a Heart Failure Society of America Scientific Statement","volume":"30","author":"Goyal","year":"2024","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.cardfail.2025.05.022_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65767-x","article-title":"Analysis of eligibility criteria in Alzheimer\u2019s and related dementias clinical trials","volume":"14","author":"Mitchell","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cardfail.2025.05.022_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079475","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.022_bib0010","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.cardfail.2025.05.022_bib0011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11897-021-00527-w","article-title":"Clinical phenotypes in patients with type 2 diabetes mellitus: characteristics, cardiovascular outcomes and treatment strategies","volume":"18","author":"Gouda","year":"2021","journal-title":"Curr Heart Fail Rep"},{"issue":"11","key":"10.1016\/j.cardfail.2025.05.022_bib0012","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1111\/dom.15768","article-title":"Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS program and CREDENCE trial","volume":"26","author":"Razaghizad","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.022_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of dementia and parkinson disease among patients with type 2 diabetes","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.022_bib0014","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.cardfail.2025.05.022_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol reports"},{"issue":"7","key":"10.1016\/j.cardfail.2025.05.022_bib0016","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.cardfail.2025.05.022_bib0017","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults","volume":"42","author":"Lipscombe","year":"2018","journal-title":"Can J diabetes"},{"issue":"10","key":"10.1016\/j.cardfail.2025.05.022_bib0018","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2337\/dc19-0783","article-title":"Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial","volume":"42","author":"Biessels","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.cardfail.2025.05.022_bib0019","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12913-018-3148-0","article-title":"Identifying diabetes cases from administrative data: a population-based validation study","volume":"18","author":"Lipscombe","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"10.1016\/j.cardfail.2025.05.022_bib0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.24095\/hpcdp.33.3.06","article-title":"Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records","volume":"33","author":"Schultz","year":"2013","journal-title":"Chronic Dis Inj Can"},{"key":"10.1016\/j.cardfail.2025.05.022_bib0021","doi-asserted-by":"crossref","first-page":"m3342","DOI":"10.1136\/bmj.m3342","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study","volume":"370","author":"Filion","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.cardfail.2025.05.022_bib0022","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pds.1360","article-title":"Application of lag-time into exposure definitions to control for protopathic bias","volume":"16","author":"Tamim","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.cardfail.2025.05.022_bib0023","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/WAD.0b013e3181a6bebc","article-title":"Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors","volume":"23","author":"Bradford","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.cardfail.2025.05.022_bib0024","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JAD-160105","article-title":"Identification of physician-diagnosed Alzheimer\u2019s disease and related dementias in population-based administrative data: a validation study using family physicians\u2019 electronic medical records","volume":"54","author":"Jaakkimainen","year":"2016","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.022_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101305","article-title":"Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: a comparison with five other classes of antidiabetic drugs","volume":"48","author":"Alkabbani","year":"2022","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.cardfail.2025.05.022_bib0026","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12933-023-01784-w","article-title":"Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction","volume":"22","author":"Gonzalez","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"10.1016\/j.cardfail.2025.05.022_bib0027","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1093\/eurheartj\/ehad273","article-title":"Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study","volume":"44","author":"Fu","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.022_bib0028","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ejhf.3464","article-title":"Timing of sodium-glucose cotransporter 2 inhibitor initiation and post-discharge outcomes in acute heart failure with diabetes: A population-based cohort study","volume":"27","author":"Wu","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.022_bib0029","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.cardfail.2025.05.022_bib0030","doi-asserted-by":"crossref","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.cardfail.2025.05.022_bib0031","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1212\/WNL.0000000000012777","article-title":"Applying propensity score methods in clinical research in neurology","volume":"97","author":"Austin","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.cardfail.2025.05.022_bib0032","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.cardfail.2025.05.022_bib0033","first-page":"1561","article-title":"Identifying patients with atrial fibrillation in administrative data","volume":"32","author":"Tu","year":"2016","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.cardfail.2025.05.022_bib0034","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.cardfail.2025.05.022_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2024.101581","article-title":"Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase iv inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: a population-based cohort study","volume":"50","author":"Hong","year":"2024","journal-title":"Diabetes Metab"},{"issue":"13","key":"10.1016\/j.cardfail.2025.05.022_bib0036","first-page":"2575","article-title":"Cardiovascular comorbidities, inflammation, and cerebral small vessel disease","volume":"117","author":"Evans","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.cardfail.2025.05.022_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14324","article-title":"Canadian Stroke Best Practice Recommendations: Vascular cognitive impairment, 7th edition practice guidelines update, 2024","volume":"21","author":"Swartz","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.cardfail.2025.05.022_bib0038","article-title":"Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment","volume":"6","author":"Smith","year":"2020","journal-title":"Alzheimer\u2019s Dement (New York, N Y)"},{"issue":"1","key":"10.1016\/j.cardfail.2025.05.022_bib0039","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei","year":"2024","journal-title":"Transl Neurodegener"},{"issue":"1","key":"10.1016\/j.cardfail.2025.05.022_bib0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-024-02255-6","article-title":"SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian randomization study","volume":"23","author":"Lv","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.022_bib0041","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.022_bib0042","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ehf2.14601","article-title":"Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease","volume":"11","author":"Sharma","year":"2023","journal-title":"ESC Hear Fail"},{"issue":"24","key":"10.1016\/j.cardfail.2025.05.022_bib0043","doi-asserted-by":"crossref","first-page":"e2956","DOI":"10.1212\/WNL.0000000000012113","article-title":"Kidney function, kidney function decline, and the risk of dementia in older adults: a registry-based study","volume":"96","author":"Xu","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.022_bib0044","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1002\/alz.14048","article-title":"Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population-based cohort study","volume":"20","author":"Tang","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.cardfail.2025.05.022_bib0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial","volume":"321","author":"Williamson","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.022_bib0046","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1474-4422(08)70143-1","article-title":"Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial","volume":"7","author":"Peters","year":"2008","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.cardfail.2025.05.022_bib0047","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cardfail.2021.10.008","article-title":"Randomized controlled trial of a cognitive intervention to improve memory in heart failure","volume":"28","author":"Pressler","year":"2022","journal-title":"J Card Fail"},{"issue":"12","key":"10.1016\/j.cardfail.2025.05.022_bib0048","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.022_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","volume":"73","author":"Tang","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"10","key":"10.1016\/j.cardfail.2025.05.022_bib0050","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.7326\/M23-3220","article-title":"Sodium-glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia\u202f: a population-based cohort study","volume":"177","author":"Hong","year":"2024","journal-title":"Ann Intern Med"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:10:59Z","timestamp":1776172259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916425002921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1071916425002921"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.022","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose Cotransporter-2 Inhibitor Initiation and Incident Dementia in Heart Failure With Diabetes: A Population-based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}